Neurenati Therapeutics, a biotech company dedicated to developing therapies for rare diseases secures $1.38million in funding.
The investment was made by the Quebec government through the Impulsion PME programme. The second close included angels. The money will be used by the business to efficiently move NEU-001 closer to clinical testing.
Read also – CA-based Vorlon Secures undisclosed amount in Series A Round Funding
The biotech business Neurenati Therapeutics, led by CEO and President Maxime Ranger, is committed to creating treatments for uncommon illnesses. The first piece of technology focuses on Hirschsprung disease (HSCR), a potentially fatal gastrointestinal (GI) birth abnormality marked by nerve loss in certain areas of the lower gastrointestinal tract.
About Neurenati Therapeutics
Innovative biotechnology business Neurenati Therapeutics is creating a novel treatment for Hirschsprung’s illness. The rare illness specialist Nicolas Pilon and the neuro-gastroenterology specialist Rodolphe Soret have joined forces to create a novel treatment for Hirschsprung’s disease.
